MENRIUM 5-2
LOE ApproachingNDAORALTABLET
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MENRIUM 5-2 is an oral tablet small-molecule drug approved by Roche in 1966 for an undisclosed indication. The specific mechanism of action and therapeutic area are not documented in available records.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal current commercial activity, career opportunities are limited to maintenance and transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings reflect this product's mature, de-prioritized status within Roche's portfolio. Career development on MENRIUM 5-2 would focus on transition management, compliance, and portfolio rationalization rather than growth or innovation.
Product Manager (Legacy)Regulatory Affairs Specialist
Worked on MENRIUM 5-2 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.